Vertaile menetelmiä
Tarkastele valitsemiasi menetelmiä rinnakkain; eroavat rivit korostetaan.
| MelasQoL (Melasma Quality of Life Scale)× | POEM (Patient-Oriented Eczema Measure)× | |
|---|---|---|
| Tieteenala | Ihotautioppi | Ihotautioppi |
| Menetelmäperhe | Process / pipeline | Process / pipeline |
| Syntyvuosi≠ | 2006 | 2004 |
| Kehittäjä≠ | Cestari TF, Hexsel D | Charman CR, Venn AJ, Williams HC |
| Tyyppi | Self-report | Self-report |
| Alkuperäislähde≠ | Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20. link ↗ | Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519. DOI ↗ |
| Rinnakkaisnimet | Melasma-QoL | POEM Score |
| Liittyvät≠ | 3 | 2 |
| Tiivistelmä≠ | MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes. | The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care. |
| ScholarGateAineisto ↗ |
|
|